Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros




Base de datos
Asunto de la revista
Intervalo de año de publicación
1.
Sci Rep ; 7: 45768, 2017 03 31.
Artículo en Inglés | MEDLINE | ID: mdl-28361969

RESUMEN

The absence of highly specific markers for malignant mesothelioma (MM) has served an obstacle for its diagnosis and development of molecular-targeting therapy against MM. Here, we show that a novel mucin-like membrane protein, sialylated protein HEG homolog 1 (HEG1), is a highly specific marker for MM. A monoclonal antibody against sialylated HEG1, SKM9-2, can detect even sarcomatoid and desmoplastic MM. The specificity and sensitivity of SKM9-2 to MM reached 99% and 92%, respectively; this antibody did not react with normal tissues. This accurate discrimination by SKM9-2 was due to the recognition of a sialylated O-linked glycan with HEG1 peptide. We also found that gene silencing of HEG1 significantly suppressed the survival and proliferation of mesothelioma cells; this result suggests that HEG1 may be a worthwhile target for function-inhibition drugs. Taken together, our results indicate that sialylated HEG1 may be useful as a diagnostic and therapeutic target for MM.


Asunto(s)
Anticuerpos Monoclonales/inmunología , Neoplasias Pulmonares/diagnóstico , Neoplasias Pulmonares/inmunología , Proteínas de la Membrana/inmunología , Mesotelioma/diagnóstico , Mesotelioma/inmunología , Anticuerpos Monoclonales/metabolismo , Biomarcadores de Tumor/inmunología , Biomarcadores de Tumor/metabolismo , Línea Celular Tumoral , Proliferación Celular , Glicosilación , Humanos , Neoplasias Pulmonares/metabolismo , Proteínas de la Membrana/genética , Proteínas de la Membrana/metabolismo , Mesotelioma/metabolismo , Mesotelioma Maligno , Sensibilidad y Especificidad
2.
PLoS One ; 10(10): e0140750, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26474319

RESUMEN

BACKGROUND: SLURP1 is the causal gene for Mal de Meleda (MDM), an autosomal recessive skin disorder characterized by diffuse palmoplantar keratoderma and transgressive keratosis. Moreover, although SLURP1 likely serves as an important proliferation/differentiation factor in keratinocytes, the possible relation between SLURP1 and other skin diseases, such as psoriasis and atopic dermatitis, has not been studied, and the pathophysiological control of SLURP1 expression in keratinocytes is largely unknown. OBJECTIVES: Our aim was to examine the involvement of SLURP1 in the pathophysiology of psoriasis using an imiquimod (IMQ)-induced psoriasis model mice and normal human epidermal keratinocytes (NHEKs). RESULTS: SLURP1 expression was up-regulated in the skin of IMQ-induced psoriasis model mice. In NHEKs stimulated with the inflammatory cytokines IL-17, IL-22 and TNF-α, which are reportedly expressed in psoriatic lesions, SLURP1 mRNA expression was significantly up-regulated by IL-22 but not the other two cytokines. The stimulatory effect of IL-22 was completely suppressed in NHEKs treated with a STAT3 inhibitor or transfected with siRNA targeting STAT3. Because IL-22 induces production of antimicrobial proteins in epithelial cells, the antibacterial activity of SLURP1 was assessed against Staphylococcus aureus (S. aureus), which is known to be associated with disease severity in psoriasis. SLURP1 significantly suppressed the growth of S. aureus. CONCLUSIONS: These results indicate SLURP1 participates in pathophysiology of psoriasis by regulating keratinocyte proliferation and differentiation, and by suppressing the growth of S. aureus.


Asunto(s)
Antígenos Ly/genética , Interleucinas/farmacología , Psoriasis/microbiología , Factor de Transcripción STAT3/metabolismo , Staphylococcus aureus/crecimiento & desarrollo , Regulación hacia Arriba/efectos de los fármacos , Activador de Plasminógeno de Tipo Uroquinasa/genética , Aminoquinolinas/farmacología , Animales , Antígenos Ly/metabolismo , Femenino , Homeostasis/efectos de los fármacos , Humanos , Imiquimod , Queratinocitos/citología , Queratinocitos/efectos de los fármacos , Queratinocitos/metabolismo , Ratones , Ratones Endogámicos BALB C , Psoriasis/inducido químicamente , Psoriasis/genética , Psoriasis/metabolismo , Piel/efectos de los fármacos , Piel/metabolismo , Piel/microbiología , Activador de Plasminógeno de Tipo Uroquinasa/metabolismo , Interleucina-22
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA